Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15776738 | 0.85 | HTR6 (0.51) | HTR6L3MBTL1NR1H2EPHX1AKR1C3 | |
| SCHEMBL15776173 | 0.85 | HTR6 (0.51) | HTR6L3MBTL1NR1H2NR1H3EPHX1 | |
| SCHEMBL29353520 | 0.85 | HTR6 (0.51) | HTR6L3MBTL1NR1H2EPHX1AKR1C3 | |
| SCHEMBL29354113 | 0.85 | HTR6 (0.51) | HTR6L3MBTL1NR1H2NR1H3EPHX1 | |
| SCHEMBL2724803 | 0.84 | AKR1C3 (0.53) | HTR6L3MBTL1PDE10AAKR1C3 | |
| SCHEMBL2999358 | 0.82 | HTR6 (0.48) | HTR6L3MBTL1NR1H2EPHX1GPR119 | |
| SCHEMBL273000 | 0.82 | L3MBTL1 (0.63) | HTR6L3MBTL1NR1H2NR1H3EPHX1 | |
| SCHEMBL17442763 | 0.80 | HTR6 (0.46) | HTR6L3MBTL1NR1H2NR1H3EPHX1 | |
| SCHEMBL15777186 | 0.78 | L3MBTL1 (0.45) | HTR6L3MBTL1NR1H2NR1H3EPHX1 | |
| SCHEMBL1241271 | 0.78 | L3MBTL1 (0.45) | HTR6L3MBTL1NR1H2NR1H3EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212138-B2 | Use of derivatives of indoles for the treatment of cancer | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-12-15 | — | — | US | disclosed |
| US-20140235654-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-08-21 | — | — | US | disclosed |
| US-20130131084-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235654-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | HTR6 26/4885L3MBTL1 3854/4885NR1H2 2486/4885 |
| US-20130131084-A1 | USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | HTR6 26/4885L3MBTL1 3854/4885NR1H2 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.